Hepatic Antiviral Drugs Market Growth and Revenue Strategy by 2029

Antiviral drugs are a type of medicine that is used to treat viral illnesses like HIV, herpes, hepatitis, and influenza. Vaccines are the most common form of administration for these medications. Furthermore, the majority of these medications are used to treat specific viral infections, but a select handful (broad-spectrum antiviral treatments) are effective against different virus forms. Antiviral medications used to treat viral infections of the liver, such as hepatitis, are known as hepatic antiviral agents.

In recent years, the hepatic antiviral drugs market is anticipated to grow rapidly during the forecast period. According to the 2019 study "Burden of Liver Diseases in the World," liver illness causes roughly 2 million fatalities per year worldwide, with 1 million deaths owing to cirrhosis complications and 1 million deaths due to viral hepatitis and hepatocellular cancer. Cirrhosis is the 11th most prevalent cause of mortality globally, while liver cancer is the 16th most common cause of death. In addition, chronic liver disease mortality in the United States is predicted to climb, owing to an increase in non-alcoholic fatty liver disease (NAFLD). The increased prevalence of liver illnesses aided in the market's expansion.

Data Bridge Market Research analyses that the hepatic antiviral drugs market was valued at USD 16.11 billion in 2021 and is expected to reach USD 23.05 billion by 2029, registering a CAGR of 4.58% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

North America and Europe dominate the hepatic antiviral drugs market because of the growing prevalence of auto-immune diseases in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Read Full Report Summary @ https://www.databridgemarketresearch.com/reports/global-hepatic-antiviral-drugs-market

Asia-Pacific are expected to grow during the forecast period due to number of population and rising prevalence of hepatic diseases in this region.

Some of the major players operating in the hepatic antiviral drugs market are:

Related Reports:

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”

Contact: 

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

Article source: https://article-realm.com/article/Sports-Recreation/43201-Hepatic-Antiviral-Drugs-Market-Growth-and-Revenue-Strategy-by-2029.html